Organization | Associació per a la Recerca Oncologica, Spain

Associació per a la Recerca Oncologica, Spain Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2012

NCT01577784

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Associació per a la Recerca Oncologica, Spain

Active Ingredients

Drugs in Phase 3 Trials (2)

cabazitaxel (jevtana kit) (1 trial)

vinflunine (1 trial)

Drugs in Phase 2 Trials (8)

avelumab (bavencio) (1 trial)

carboplatin (paraplatin) (1 trial)

everolimus (zortress) (1 trial)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

pazopanib (votrient) (1 trial)

sapanisertib (1 trial)

sunitinib (sutent) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Kidney Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 10